What are the indications, dosing (including renal adjustments), contraindications, and side effects of ciprofloxacin?

Ciprofloxacin: Indications, Dosing, Contraindications, and Side Effects

Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic effective for treating urinary tract infections, pyelonephritis, respiratory infections, skin/soft tissue infections, bone/joint infections, and certain bioterrorism-related infections, but should be reserved for situations where alternative agents cannot be used due to concerns about collateral damage and resistance development.

Indications

FDA-Approved Uses 1

Ciprofloxacin is indicated for multiple bacterial infections, though specific FDA-approved indications are limited. The drug demonstrates activity against gram-negative organisms including Pseudomonas aeruginosa and some gram-positive organisms 2.

Guideline-Recommended Uses

Urinary Tract Infections:

• Acute uncomplicated cystitis: Fluoroquinolones including ciprofloxacin are highly efficacious in 3-day regimens but should be considered alternative agents only when first-line options cannot be used 3
• Acute pyelonephritis: Oral ciprofloxacin 500 mg twice daily for 7 days is appropriate when fluoroquinolone resistance is <10% in the community 3. An initial 400 mg IV dose may be added, or alternatively, a single dose of ceftriaxone 1g IV 3
• Extended-release formulation: 1000 mg daily for 7 days is also effective 3

Tularemia:

• Ciprofloxacin is now considered a first-line agent for tularemia treatment based on extensive clinical experience 4
• Adult dosing: 400 mg IV every 8 hours OR 750 mg orally every 12 hours 4
• Pediatric dosing: 10 mg/kg IV every 8-12 hours (max 400 mg/dose) OR 15 mg/kg orally every 8-12 hours (max 500 mg every 8 hours or 750 mg every 12 hours) 4

Non-Tuberculous Mycobacterial Disease:

• Doses of 500-750 mg twice daily have been used off-label 5
• Target trough level: 1-1.5 mg/L; peak level: 3-4.5 mg/L 5

Disseminated Gonococcal Infection:

• 500 mg orally twice daily to complete one week of therapy after initial parenteral treatment 6

Dosing

Standard Adult Dosing 1

Indication	Dose	Frequency	Duration
Uncomplicated cystitis	250 mg	Every 12 hours	3 days
Pyelonephritis	500 mg	Every 12 hours	7 days
Pyelonephritis (XR)	1000 mg	Every 24 hours	7 days
Severe infections	750 mg	Every 12 hours	Variable
Tularemia	750 mg	Every 12 hours	10-21 days

Pediatric Dosing 4, 1

• General: 20 mg/kg (max 750 mg) twice daily
• Tularemia: 15 mg/kg every 8-12 hours orally (max 500 mg every 8 hours or 750 mg every 12 hours)
• IV: 10 mg/kg every 8-12 hours (max 400 mg/dose)

Renal Dose Adjustments 1, 7

Critical consideration: Ciprofloxacin is 80% renally cleared 8. Dosage adjustment is essential when creatinine clearance falls below specific thresholds.

• CrCl 30-50 mL/min: Reduce dose by 50% OR extend interval to every 18-24 hours
• CrCl <30 mL/min or hemodialysis: 250-500 mg every 24 hours 7
• After hemodialysis: Give dose after dialysis session (drug is not significantly removed by dialysis) 8

Important: For concentration-dependent killing, prolonging the interval while maintaining dose may be superior to dose reduction 9. Consider 500 mg every 24 hours rather than 250 mg every 12 hours in renal failure 9.

Hepatic Dosing 8

No adjustment necessary—drug levels are not affected by hepatic disease 8. However, use with caution in severe liver disease.

Contraindications

Absolute Contraindications 1

1. Pregnancy and lactation 8: Teratogenic effects demonstrated in animal studies
2. Concomitant tizanidine use 1: Risk of severe hypotension and sedation
3. Known hypersensitivity to ciprofloxacin or other fluoroquinolones

Relative Contraindications/Precautions 6, 10, 1

• Children and adolescents ≤17 years: Historically contraindicated due to arthropathy concerns in animal studies 6. However, recent evidence shows musculoskeletal events occur in only 9.3% of pediatric patients (vs 6% with comparators), with most resolving within 30 days 1. Now considered acceptable for serious infections when alternatives are inadequate 4, 10
• QT prolongation risk: Avoid in patients with known QT prolongation, uncorrected hypokalemia/hypomagnesemia, or concurrent use of Class IA/III antiarrhythmics 5, 11
• Elderly patients on corticosteroids: Significantly increased tendon rupture risk 1, 11

Administration Considerations

Drug-Food Interactions 1, 12

• Antacids/polyvalent cations (aluminum, magnesium, calcium, iron, zinc): Reduce absorption by up to 90% 5, 1
• Timing: Take ciprofloxacin 1-2 hours before OR 4 hours after antacids or calcium-containing products 5
• Enteral feeding: Discontinue feeding 2 hours before and 2 hours after ciprofloxacin administration 12

Pharmacokinetics 1

• Bioavailability: ~70% oral
• Peak concentration: 1-2 hours after oral dose
• Half-life: 4 hours (normal renal function); prolonged in renal impairment
• Distribution: Excellent tissue penetration; CSF levels 10% of serum
• Metabolism: 15% hepatic (4 metabolites)
• Excretion: 40-50% unchanged in urine

Adverse Effects

Common (>1%) 1, 13

• Gastrointestinal (4.9%): Nausea (2.5%), diarrhea (1.6%), vomiting (1%)
• Hepatic (4.4%): Transient LFT elevations (1.3%)
• CNS (1.5%): Headache, dizziness, insomnia
• Dermatologic (1.1%): Rash, pruritus
• Overall discontinuation rate: 1.5% 13

Serious (<1%) 5, 1, 11

Musculoskeletal:

• Tendinitis/tendon rupture: Achilles tendon most common; risk increases with age >60 years, corticosteroid use, and renal disease 1, 11
• Timing: Can occur during treatment or months after completion 1
• Action: Discontinue immediately if tendon pain develops

Cardiovascular:

• QT prolongation: Rare but serious; monitor ECG at baseline, 2 weeks, and after adding QT-prolonging medications 5
• Risk factors: Elderly patients, uncorrected electrolyte abnormalities, concurrent QT-prolonging drugs 11

Neurologic:

• CNS effects more concerning in elderly with pre-existing CNS impairment (epilepsy, arteriosclerosis) 11
• Confusion, tremor, seizures (rare)

Dermatologic:

• Photosensitivity 5, 8
• Stevens-Johnson syndrome/toxic epidermal necrolysis (rare) 5

Hypersensitivity:

• Anaphylaxis (rare) 1

Monitoring Requirements 5

• ECG: Baseline, 2 weeks, and after adding interacting medications
• Blood glucose: Regular monitoring in diabetics (hypoglycemia risk)
• Renal function: Particularly in elderly patients
• Routine labs: CBC, electrolytes, LFTs intermittently throughout treatment

Drug Interactions

Major Interactions 5, 1

1. Theophylline: Decreased clearance, increased theophylline levels and toxicity risk 1
2. Warfarin: Enhanced anticoagulant effect; monitor INR closely 5
3. Corticosteroids: Synergistic increase in tendon rupture risk 1, 11
4. QT-prolonging drugs: Additive QT prolongation (domperidone, metoclopramide, 5HT3 antagonists, Class IA/III antiarrhythmics) 5
5. Probenecid: 50% reduction in renal clearance, 50% increase in systemic concentration 1

Clinical Pearls

When to use ciprofloxacin:

• Pyelonephritis in areas with <10% fluoroquinolone resistance 3
• Tularemia (now first-line) 4
• Serious infections requiring anti-pseudomonal coverage when alternatives inadequate
• Complicated UTIs in pediatric patients when benefits outweigh risks 1

When to avoid:

• Uncomplicated cystitis (reserve for when alternatives cannot be used) 3
• Pregnancy/lactation 8
• Patients >60 years on corticosteroids (tendon rupture risk) 1, 11
• Known QT prolongation or high-risk cardiac patients 11

Common pitfalls:

• Failing to adjust dose in renal impairment (leads to toxicity) 7
• Co-administering with antacids/dairy (leads to treatment failure) 1, 12
• Using as first-line for simple cystitis (contributes to resistance) 3
• Ignoring tendon pain in elderly patients (can progress to rupture) 1